Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Finafloxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.54 |
| ▸ | HPGD | P15428 | 4/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.49 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | CLK2 | P49760 | 1/20 | 0.49 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
| ▸ | TOP2A | P11388 | 5/20 | 0.43 |
| ▸ | TOP2B | Q02880 | 5/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Finafloxacin SCHEMBL7608318 | 1.00 | ALDH1A1 (0.54) | ALDH1A1KDM4EHPGDHSD17B10MEN1 | |
| Finafloxacin SCHEMBL7610665 | 1.00 | ALDH1A1 (0.54) | ALDH1A1KDM4EHPGDHSD17B10MEN1 | |
| Finafloxacin SCHEMBL29378815 | 0.99 | ALDH1A1 (0.55) | ALDH1A1KDM4EHPGDHSD17B10MEN1 | |
| Finafloxacin SCHEMBL7664508 | 0.99 | ALDH1A1 (0.55) | ALDH1A1KDM4EHPGDHSD17B10MEN1 | |
| Finafloxacin SCHEMBL7660879 | 0.99 | ALDH1A1 (0.55) | ALDH1A1KDM4EHPGDHSD17B10MEN1 | |
| SCHEMBL9182746 | 0.92 | ALDH1A1 (0.54) | ALDH1A1KDM4EHPGDHSD17B10MEN1 | |
| SCHEMBL8803776 | 0.92 | ALDH1A1 (0.54) | ALDH1A1KDM4EHPGDHSD17B10MEN1 | |
| SCHEMBL15791569 | 0.90 | ALDH1A1 (0.48) | ALDH1A1KDM4EHPGDHSD17B10MEN1 | |
| SCHEMBL7610667 | 0.90 | ALDH1A1 (0.45) | ALDH1A1KDM4EHPGDHSD17B10MEN1 | |
| SCHEMBL7608326 | 0.90 | ALDH1A1 (0.45) | ALDH1A1KDM4EHPGDHSD17B10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 257 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624057-B2 | Bisphosphonate quinolone conjugates and uses thereof | BIOVINC, LLC (US) | 2026-05-12 | — | — | US | claimed |
| US-12329730-B2 | Thermoresponsive hydrogel containing polymer microparticles for controlled drug delivery | University of Pittsburgh—Of the Commonweatlh System of Higher Education (US) | 2025-06-17 | — | — | US | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| US-12312632-B2 | Systems and methods for performing antimicrobial susceptibility testing | SeLux Diagnostics, Inc. (US) | 2025-05-27 | — | — | US | claimed |
| CN-118340907-A | Polymer conjugates comprising bioactive agents | 波利艾克蒂瓦有限公司 | 2024-07-16 | — | — | CN | claimed |
| US-20240182504-A1 | BISPHOSPHONATE QUINOLONE CONJUGATES AND USES THEREOF | BIOVINC LLC (US) | 2024-06-06 | — | — | US | claimed |
| EP-3242667-B1 | FINAFLOXACIN FOR USE IN THE TREATMENT OF URINARY TRACT INFECTIONS | MERLION PHARMACEUTICALS GMBH (DE) | 2024-06-05 | — | — | EP | claimed |
| US-11998615-B2 | Functionalized nanoparticles and their use in treating bacterial infections | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-06-04 | — | — | US | claimed |
| US-20240102074-A1 | SYSTEMS AND METHODS FOR PERFORMING ANTIMICROBIAL SUSCEPTIBILITY TESTING | SeLux Diagnostics, Inc. | 2024-03-28 | — | — | US | claimed |
| US-11845976-B2 | Systems and methods for performing antimicrobial susceptibility testing | SeLux Diagnostics, Inc. (US) | 2023-12-19 | — | — | US | claimed |
| US-20220339293-A1 | FUNCTIONALIZED NANOPARTICLES AND THEIR USE IN TREATING BACTERIAL INFECTIONS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2022-10-27 | — | — | US | claimed |
| US-11390900-B2 | Antimicrobial cartridges and processes for multiplexed antimicrobial susceptibility testing | SeLux Diagnostics, Inc. (US) | 2022-07-19 | — | — | US | claimed |
| EP-4022079-A1 | SYSTEMS AND METHODS FOR PERFORMING ANTIMICROBIAL SUSCEPTIBILITY TESTING | Selux Diagnostics, Inc. (US) | 2022-07-06 | — | — | EP | claimed |
| EP-3996751-A1 | FUNCTIONALIZED NANOPARTICLES AND THEIR USE IN TREATING BACTERIAL INFECTIONS | The Board Of Trustees Of The Leland Stanford Junior University (US) | 2022-05-18 | — | — | EP | claimed |
| US-11291671-B2 | Solid drug implants for intracochlear delivery of therapeutics for the treatment of Otic disorders | O-RAY PHARMA, INC. (US) | 2022-04-05 | — | — | US | claimed |
| WO-2022047234-A1 | DRUG COMBINATION KITS AND METHODS OF DRUG DELIVERY | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-03-03 | — | — | WO | claimed |
| CN-105920603-B | Treatment of erectile dysfunction and other indications | 战略科学与技术有限责任公司 | 2022-02-11 | — | — | CN | claimed |
| WO-2022031761-A2 | TARGETED DELIVERY OF THERAPEUTIC AGENTS | SEPELO THERAPEUTICS, LLC (US) | 2022-02-10 | — | — | WO | claimed |
| EP-0946176-B1 | THE USE OF 7-(2-OXA-5,8-DIAZABICYCLO 4.3.0]NON-8-YL)-QUINOLONE CARBOXYLIC ACID AND NAPHTHYRIDON CARBOXYLIC ACID DERIVATIVES FOR MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF HELICOBACTER PYLORI INFECTIONS AND ASSOCIATED GASTRODUODENAL DISEASES | BAYER AG (DE) | 2002-03-27 | — | — | EP | claimed |
| US-6133260-A | Use of 7-(2-oxa-5,8-diazabicyclo[4.3.0]non-8-yl)-quinolone carboxylic acid and naphthyridon carboxylic acid derivatives for the treatment of Helicobacter pylori infections and associated gastroduodenal diseases | BAYER AKTIENGESELLSCHAFT (DE) | 2000-10-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240182504-A1 | BISPHOSPHONATE QUINOLONE CONJUGATES AND USES THEREOF | BPGM, PHPT1, NQO2 | ALDH1A1 2346/4885KDM4E 3437/4885HPGD 266/4885 |
| US-12624057-B2 | Bisphosphonate quinolone conjugates and uses thereof | PTMS, CYP24A1, PHPT1 | ALDH1A1 4057/4885KDM4E 476/4885HPGD 590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.